DNA and gene chip market seen reaching $16.99B by 2030

The Business Research Company projects the DNA and gene chip market will grow from $9.2 billion in 2025 to $10.45 billion in 2026, then reach $16.99 billion by 2030. The report points to early cancer detection, genomics research, AI-driven analytics and personalized medicine as the main demand drivers.

Why it matters: - DNA and gene chips are becoming more central to genomics, molecular diagnostics and personalized healthcare. - The market’s growth signal points to rising demand for tools that can detect mutations, profile gene expression and support earlier disease detection. - The report also shows where demand is likely to concentrate next, especially in North America and faster-growing Asia-Pacific markets.

What happened: - The Business Research Company published a DNA and gene chip market report on August 5, 2026. - The report projects the market will grow from $9.2 billion in 2025 to $10.45 billion in 2026. - The report forecasts the market will reach $16.99 billion by 2030. - The company expects a 13.6% CAGR from 2025 to 2026 and a 12.9% CAGR through 2030. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report adds market attractiveness scoring, TAM analysis, company scoring matrices, Excel dashboards, market hotspot infographics and updated trend analysis. - More information

The details: - A DNA and gene chip is a microdevice with tiny DNA probes fixed on a solid surface. - The chips detect DNA sequences by measuring whether sample DNA binds to the probes on the chip. - The technology identifies specific genetic mutations and helps analyze gene expression levels. - The chips are used to detect mutations linked to disease and to support diagnostics. - The report says historical growth was driven by genomic research initiatives, wider molecular diagnostic adoption, cancer research, advanced microarray platforms and stronger academic genomics funding. - Future growth drivers include personalized medicine, genomics-based pharmaceutical discovery, large-scale genetic screening, AI-powered genomic analytics and agricultural genomics. - Early cancer diagnosis is one of the main demand drivers because DNA and gene chips can map genetic and epigenetic changes in cancer cells and analyze genomic regulatory elements. - A May 2025 National Cancer Institute report projected about 2,041,910 new U.S. cancer cases and 618,120 cancer deaths in 2025. - North America held the largest market share in 2025. - Asia-Pacific is expected to grow fastest over the forecast period.

Between the lines: - The report is framing DNA and gene chips as a cross-sector technology, not just a research tool, because demand now spans healthcare, drug discovery and agriculture. - The strongest growth case appears to be broader adoption of genomic data analysis, where AI could help make large-scale testing more practical and useful. - The regional split suggests the market is mature in North America but still has more expansion runway in Asia-Pacific.

What's next: - The market is on track for continued double-digit growth through 2030 if genomics investment and early screening demand keep rising. - Wider use of AI in genomic analytics and expansion of population-scale screening programs could further lift adoption. - The full report is available here.